 Ross Kedl
Concepts (473)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| CD8-Positive T-Lymphocytes | 57 | 2023 | 702 | 8.890 |
Why?
| | Immunologic Memory | 26 | 2023 | 313 | 5.590 |
Why?
| | Dendritic Cells | 30 | 2022 | 442 | 4.470 |
Why?
| | T-Lymphocytes | 22 | 2023 | 1774 | 2.680 |
Why?
| | Lymphocyte Activation | 27 | 2022 | 1067 | 2.420 |
Why?
| | Vaccines, Subunit | 6 | 2021 | 42 | 2.320 |
Why?
| | Antigen Presentation | 10 | 2017 | 194 | 2.200 |
Why?
| | Antigens | 10 | 2017 | 320 | 1.930 |
Why?
| | CD40 Antigens | 11 | 2021 | 80 | 1.760 |
Why?
| | Membrane Glycoproteins | 11 | 2014 | 446 | 1.620 |
Why?
| | Mice, Inbred C57BL | 45 | 2023 | 4908 | 1.600 |
Why?
| | Interleukin-15 | 6 | 2022 | 77 | 1.600 |
Why?
| | CD27 Ligand | 4 | 2015 | 9 | 1.580 |
Why?
| | Vaccines | 6 | 2019 | 380 | 1.550 |
Why?
| | Adjuvants, Immunologic | 14 | 2018 | 207 | 1.510 |
Why?
| | T-Lymphocyte Subsets | 8 | 2014 | 396 | 1.490 |
Why?
| | Interleukins | 5 | 2021 | 242 | 1.400 |
Why?
| | Interferon Type I | 7 | 2017 | 129 | 1.380 |
Why?
| | CD4-Positive T-Lymphocytes | 15 | 2021 | 984 | 1.300 |
Why?
| | Mice | 70 | 2023 | 15520 | 1.290 |
Why?
| | Lymph Nodes | 6 | 2017 | 455 | 1.270 |
Why?
| | Animals | 90 | 2023 | 33381 | 1.230 |
Why?
| | CD8 Antigens | 4 | 2019 | 71 | 1.200 |
Why?
| | Listeria monocytogenes | 5 | 2023 | 110 | 1.160 |
Why?
| | Immunity, Innate | 7 | 2022 | 745 | 1.130 |
Why?
| | Mice, Transgenic | 21 | 2021 | 2025 | 1.130 |
Why?
| | Toll-Like Receptor 7 | 10 | 2014 | 35 | 1.070 |
Why?
| | Interleukin-27 | 3 | 2021 | 12 | 1.060 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 3 | 2015 | 27 | 1.050 |
Why?
| | Ovalbumin | 12 | 2018 | 165 | 1.020 |
Why?
| | Mice, Knockout | 24 | 2022 | 2680 | 1.000 |
Why?
| | T-Lymphocytes, Helper-Inducer | 3 | 2021 | 130 | 0.990 |
Why?
| | Emergency Responders | 2 | 2021 | 34 | 0.970 |
Why?
| | Cross-Priming | 4 | 2011 | 20 | 0.890 |
Why?
| | Cancer Vaccines | 7 | 2016 | 139 | 0.890 |
Why?
| | Epitopes, T-Lymphocyte | 8 | 2021 | 170 | 0.830 |
Why?
| | Listeriosis | 2 | 2019 | 60 | 0.820 |
Why?
| | Asymptomatic Infections | 1 | 2021 | 23 | 0.790 |
Why?
| | Interleukin-12 | 7 | 2015 | 110 | 0.790 |
Why?
| | Immunity | 2 | 2019 | 129 | 0.780 |
Why?
| | Signal Transduction | 15 | 2022 | 4709 | 0.730 |
Why?
| | Adaptive Immunity | 5 | 2020 | 161 | 0.710 |
Why?
| | Lymphocyte Depletion | 2 | 2019 | 119 | 0.690 |
Why?
| | Poly I-C | 6 | 2015 | 55 | 0.680 |
Why?
| | B-Lymphocytes | 3 | 2023 | 770 | 0.680 |
Why?
| | Immunity, Cellular | 5 | 2015 | 270 | 0.660 |
Why?
| | Antigens, Viral | 2 | 2014 | 181 | 0.660 |
Why?
| | Interferon-gamma | 4 | 2023 | 736 | 0.640 |
Why?
| | Cell Differentiation | 12 | 2023 | 1753 | 0.630 |
Why?
| | Receptors, Antigen, T-Cell | 9 | 2020 | 632 | 0.620 |
Why?
| | Toll-Like Receptors | 7 | 2020 | 167 | 0.610 |
Why?
| | Melanoma, Experimental | 4 | 2022 | 118 | 0.610 |
Why?
| | Adoptive Transfer | 11 | 2020 | 204 | 0.610 |
Why?
| | Aminoquinolines | 4 | 2005 | 20 | 0.600 |
Why?
| | Vaccination | 8 | 2021 | 1222 | 0.570 |
Why?
| | Receptors, Cell Surface | 5 | 2005 | 367 | 0.560 |
Why?
| | Bystander Effect | 1 | 2016 | 14 | 0.560 |
Why?
| | Receptor, Interferon alpha-beta | 3 | 2017 | 22 | 0.560 |
Why?
| | Cell Movement | 8 | 2022 | 896 | 0.550 |
Why?
| | Endothelium, Lymphatic | 1 | 2015 | 12 | 0.540 |
Why?
| | Squalene | 1 | 2015 | 5 | 0.520 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2023 | 210 | 0.520 |
Why?
| | H-2 Antigens | 5 | 2016 | 111 | 0.510 |
Why?
| | Breeding | 1 | 2014 | 56 | 0.510 |
Why?
| | Housing, Animal | 1 | 2014 | 46 | 0.490 |
Why?
| | Caspase 1 | 1 | 2015 | 143 | 0.490 |
Why?
| | Bacterial Vaccines | 1 | 2014 | 60 | 0.490 |
Why?
| | Cell Proliferation | 6 | 2019 | 2275 | 0.490 |
Why?
| | OX40 Ligand | 2 | 2011 | 10 | 0.490 |
Why?
| | Immunotherapy, Adoptive | 1 | 2016 | 191 | 0.480 |
Why?
| | Antigens, Neoplasm | 4 | 2018 | 228 | 0.470 |
Why?
| | Viral Vaccines | 2 | 2014 | 90 | 0.470 |
Why?
| | Caspases | 1 | 2015 | 269 | 0.470 |
Why?
| | Cytotoxicity, Immunologic | 6 | 2019 | 204 | 0.470 |
Why?
| | Immunization | 9 | 2020 | 412 | 0.460 |
Why?
| | Interleukin-18 | 1 | 2015 | 228 | 0.460 |
Why?
| | Cytokines | 13 | 2019 | 1900 | 0.450 |
Why?
| | Cell Lineage | 3 | 2013 | 318 | 0.450 |
Why?
| | Antibodies, Viral | 6 | 2023 | 542 | 0.430 |
Why?
| | Endothelial Cells | 1 | 2017 | 732 | 0.420 |
Why?
| | Spike Glycoprotein, Coronavirus | 3 | 2022 | 94 | 0.420 |
Why?
| | Receptors, OX40 | 1 | 2011 | 15 | 0.420 |
Why?
| | Tumor Necrosis Factors | 1 | 2011 | 9 | 0.420 |
Why?
| | Toll-Like Receptor 4 | 1 | 2015 | 330 | 0.420 |
Why?
| | Spleen | 8 | 2019 | 510 | 0.420 |
Why?
| | T-Cell Antigen Receptor Specificity | 4 | 2016 | 41 | 0.420 |
Why?
| | Virus Diseases | 1 | 2014 | 198 | 0.420 |
Why?
| | Vaccinia | 3 | 2018 | 19 | 0.410 |
Why?
| | Immunity, Humoral | 3 | 2023 | 117 | 0.410 |
Why?
| | Up-Regulation | 5 | 2022 | 872 | 0.410 |
Why?
| | Chemokines | 4 | 2020 | 230 | 0.400 |
Why?
| | Orthomyxoviridae Infections | 3 | 2021 | 53 | 0.400 |
Why?
| | Cells, Cultured | 11 | 2019 | 4077 | 0.390 |
Why?
| | Vaccines, Conjugate | 2 | 2010 | 63 | 0.390 |
Why?
| | Pancreatic Neoplasms | 3 | 2023 | 734 | 0.380 |
Why?
| | Antigen-Presenting Cells | 5 | 2018 | 156 | 0.380 |
Why?
| | Female | 35 | 2022 | 61565 | 0.360 |
Why?
| | Humans | 40 | 2023 | 118974 | 0.340 |
Why?
| | Th1 Cells | 5 | 2019 | 133 | 0.330 |
Why?
| | Career Mobility | 1 | 2009 | 66 | 0.330 |
Why?
| | Industry | 1 | 2009 | 69 | 0.330 |
Why?
| | Lymphocyte Count | 4 | 2021 | 136 | 0.320 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 3 | 2017 | 40 | 0.310 |
Why?
| | Myeloid Cells | 4 | 2021 | 128 | 0.290 |
Why?
| | Career Choice | 1 | 2009 | 192 | 0.290 |
Why?
| | Skin Neoplasms | 2 | 2022 | 762 | 0.290 |
Why?
| | Interleukin-2 Receptor beta Subunit | 2 | 2019 | 20 | 0.290 |
Why?
| | Universities | 1 | 2009 | 347 | 0.290 |
Why?
| | Radiation Chimera | 3 | 2014 | 31 | 0.290 |
Why?
| | Viral Proteins | 2 | 2001 | 296 | 0.280 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2006 | 59 | 0.280 |
Why?
| | Oligopeptides | 2 | 2012 | 252 | 0.270 |
Why?
| | Binding, Competitive | 2 | 2003 | 205 | 0.270 |
Why?
| | CD11b Antigen | 2 | 2014 | 59 | 0.260 |
Why?
| | Mice, 129 Strain | 2 | 2017 | 75 | 0.260 |
Why?
| | CD11c Antigen | 2 | 2008 | 38 | 0.250 |
Why?
| | Repressor Proteins | 3 | 2017 | 377 | 0.250 |
Why?
| | Mice, Inbred BALB C | 10 | 2020 | 1206 | 0.240 |
Why?
| | B7-H1 Antigen | 4 | 2021 | 144 | 0.240 |
Why?
| | Seroepidemiologic Studies | 2 | 2021 | 146 | 0.240 |
Why?
| | Influenza A virus | 2 | 2021 | 90 | 0.240 |
Why?
| | Immunophenotyping | 3 | 2019 | 278 | 0.240 |
Why?
| | Cell Adhesion Molecules | 2 | 2022 | 180 | 0.220 |
Why?
| | Omentum | 1 | 2022 | 11 | 0.220 |
Why?
| | Peptide Fragments | 4 | 2016 | 702 | 0.220 |
Why?
| | Egg Proteins | 2 | 2001 | 19 | 0.220 |
Why?
| | Chemokine CXCL10 | 2 | 2022 | 40 | 0.220 |
Why?
| | Graft Rejection | 2 | 2017 | 555 | 0.220 |
Why?
| | Neoplasm Transplantation | 2 | 2006 | 245 | 0.220 |
Why?
| | Lung | 6 | 2021 | 3664 | 0.210 |
Why?
| | Immunotherapy | 5 | 2023 | 493 | 0.210 |
Why?
| | Sentinel Lymph Node | 1 | 2022 | 40 | 0.210 |
Why?
| | Transforming Growth Factor beta | 2 | 2019 | 462 | 0.210 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2022 | 1167 | 0.210 |
Why?
| | Imidazoles | 5 | 2014 | 232 | 0.210 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 16 | 0.210 |
Why?
| | Gene Rearrangement, T-Lymphocyte | 1 | 2001 | 13 | 0.210 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 22 | 0.210 |
Why?
| | Transcription Factors | 4 | 2023 | 1570 | 0.210 |
Why?
| | Microspheres | 2 | 2021 | 130 | 0.200 |
Why?
| | Portraits as Topic | 1 | 2021 | 2 | 0.200 |
Why?
| | Male | 20 | 2021 | 57801 | 0.200 |
Why?
| | Receptors, CCR2 | 1 | 2021 | 30 | 0.200 |
Why?
| | Microfilament Proteins | 1 | 2022 | 134 | 0.200 |
Why?
| | Receptors, Virus | 1 | 2021 | 78 | 0.200 |
Why?
| | Immunologic Factors | 1 | 2003 | 225 | 0.200 |
Why?
| | Immunoglobulin M | 2 | 2022 | 253 | 0.200 |
Why?
| | Immunoassay | 1 | 2021 | 101 | 0.190 |
Why?
| | Luminescent Proteins | 1 | 2001 | 174 | 0.190 |
Why?
| | Specimen Handling | 1 | 2022 | 165 | 0.190 |
Why?
| | Immunity, Mucosal | 1 | 2021 | 86 | 0.190 |
Why?
| | Monocytes | 3 | 2019 | 513 | 0.190 |
Why?
| | Transcriptional Activation | 2 | 2022 | 348 | 0.190 |
Why?
| | Macrophages | 2 | 2021 | 1324 | 0.190 |
Why?
| | Cell Communication | 4 | 2013 | 281 | 0.180 |
Why?
| | Phosphoproteins | 1 | 2022 | 308 | 0.180 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2022 | 200 | 0.180 |
Why?
| | Actins | 1 | 2022 | 404 | 0.180 |
Why?
| | Primary Cell Culture | 2 | 2021 | 155 | 0.180 |
Why?
| | Fluorescent Dyes | 1 | 2001 | 316 | 0.180 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2005 | 1171 | 0.180 |
Why?
| | Glycoproteins | 1 | 2001 | 319 | 0.180 |
Why?
| | Integrin alpha Chains | 3 | 2019 | 22 | 0.180 |
Why?
| | Disease Models, Animal | 5 | 2021 | 3730 | 0.180 |
Why?
| | Joints | 1 | 2020 | 85 | 0.180 |
Why?
| | Influenza Vaccines | 2 | 2021 | 500 | 0.170 |
Why?
| | Disease Resistance | 1 | 2019 | 29 | 0.170 |
Why?
| | Chikungunya Fever | 1 | 2020 | 63 | 0.170 |
Why?
| | Homeostasis | 2 | 2016 | 594 | 0.170 |
Why?
| | Chikungunya virus | 1 | 2020 | 63 | 0.170 |
Why?
| | Gene Expression | 2 | 2016 | 1489 | 0.170 |
Why?
| | Costimulatory and Inhibitory T-Cell Receptors | 1 | 2019 | 8 | 0.170 |
Why?
| | Antibodies, Monoclonal | 4 | 2019 | 1284 | 0.170 |
Why?
| | Aerobiosis | 1 | 2018 | 21 | 0.170 |
Why?
| | Flow Cytometry | 5 | 2016 | 1085 | 0.170 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 156 | 0.170 |
Why?
| | T-Box Domain Proteins | 1 | 2019 | 95 | 0.170 |
Why?
| | Immune Tolerance | 3 | 2012 | 334 | 0.170 |
Why?
| | Allergens | 2 | 2021 | 424 | 0.170 |
Why?
| | Peptides | 5 | 2013 | 879 | 0.160 |
Why?
| | Vaccines, DNA | 2 | 2009 | 32 | 0.160 |
Why?
| | Gene Expression Regulation | 6 | 2013 | 2445 | 0.160 |
Why?
| | Lymphocytes | 2 | 2022 | 347 | 0.160 |
Why?
| | Hypersensitivity | 1 | 2021 | 268 | 0.160 |
Why?
| | Cell Membrane | 1 | 2001 | 710 | 0.160 |
Why?
| | Antigens, CD | 4 | 2019 | 460 | 0.160 |
Why?
| | Killer Cells, Natural | 2 | 2019 | 381 | 0.150 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 471 | 0.150 |
Why?
| | Interleukin-10 | 1 | 2019 | 306 | 0.150 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2018 | 145 | 0.150 |
Why?
| | Gene Products, gag | 3 | 2006 | 38 | 0.150 |
Why?
| | Glycolysis | 1 | 2018 | 224 | 0.150 |
Why?
| | Transplantation Tolerance | 1 | 2017 | 31 | 0.150 |
Why?
| | Friend murine leukemia virus | 1 | 2017 | 30 | 0.150 |
Why?
| | Cytidine Deaminase | 1 | 2017 | 57 | 0.150 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2017 | 68 | 0.140 |
Why?
| | Melanoma | 2 | 2022 | 664 | 0.140 |
Why?
| | Antibodies | 3 | 2015 | 392 | 0.140 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2018 | 164 | 0.140 |
Why?
| | Myeloid Differentiation Factor 88 | 3 | 2011 | 95 | 0.130 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2016 | 310 | 0.130 |
Why?
| | Epitopes | 3 | 2007 | 443 | 0.130 |
Why?
| | DNA-Binding Proteins | 2 | 2018 | 1346 | 0.130 |
Why?
| | AIDS Vaccines | 2 | 2005 | 44 | 0.130 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2016 | 147 | 0.130 |
Why?
| | Adenocarcinoma | 1 | 2022 | 812 | 0.130 |
Why?
| | Caspases, Initiator | 1 | 2015 | 18 | 0.130 |
Why?
| | Host-Pathogen Interactions | 1 | 2018 | 300 | 0.130 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2015 | 41 | 0.130 |
Why?
| | Antibodies, Neutralizing | 1 | 2017 | 228 | 0.130 |
Why?
| | Immunoglobulin G | 5 | 2022 | 788 | 0.130 |
Why?
| | Antibody Formation | 2 | 2013 | 276 | 0.130 |
Why?
| | Toll-Like Receptor 9 | 2 | 2006 | 30 | 0.130 |
Why?
| | Skin Transplantation | 1 | 2015 | 58 | 0.130 |
Why?
| | Coculture Techniques | 1 | 2015 | 208 | 0.130 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 401 | 0.130 |
Why?
| | Reoviridae | 1 | 1995 | 38 | 0.130 |
Why?
| | Smallpox Vaccine | 1 | 2014 | 23 | 0.130 |
Why?
| | Receptors, Cytokine | 1 | 2014 | 33 | 0.130 |
Why?
| | STAT Transcription Factors | 1 | 2014 | 15 | 0.130 |
Why?
| | Receptors, Interleukin | 1 | 2014 | 41 | 0.130 |
Why?
| | Pandemics | 1 | 2023 | 1355 | 0.130 |
Why?
| | Interleukin-2 | 5 | 2023 | 416 | 0.130 |
Why?
| | Virus Replication | 1 | 2017 | 405 | 0.130 |
Why?
| | Liposomes | 4 | 2011 | 151 | 0.120 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2014 | 82 | 0.120 |
Why?
| | Colorado | 2 | 2021 | 4196 | 0.120 |
Why?
| | Capsid Proteins | 1 | 1995 | 70 | 0.120 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1995 | 372 | 0.120 |
Why?
| | Leukocytes, Mononuclear | 3 | 2013 | 509 | 0.120 |
Why?
| | Gangliosides | 1 | 2013 | 19 | 0.120 |
Why?
| | Growth Hormone | 1 | 2013 | 108 | 0.120 |
Why?
| | Proto-Oncogene Proteins pp60(c-src) | 1 | 2013 | 12 | 0.110 |
Why?
| | Autoantigens | 1 | 2016 | 397 | 0.110 |
Why?
| | Positive Regulatory Domain I-Binding Factor 1 | 1 | 2013 | 15 | 0.110 |
Why?
| | Phenotype | 2 | 2019 | 3003 | 0.110 |
Why?
| | Transplantation Chimera | 1 | 2013 | 51 | 0.110 |
Why?
| | Genes, MHC Class II | 1 | 2013 | 72 | 0.110 |
Why?
| | Autoimmunity | 2 | 2019 | 831 | 0.110 |
Why?
| | Clone Cells | 4 | 2001 | 248 | 0.110 |
Why?
| | Whole-Body Irradiation | 1 | 2013 | 72 | 0.110 |
Why?
| | Guidelines as Topic | 1 | 2014 | 262 | 0.110 |
Why?
| | Muramidase | 1 | 2012 | 72 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2012 | 102 | 0.110 |
Why?
| | Vaccinia virus | 2 | 2010 | 34 | 0.110 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2007 | 355 | 0.110 |
Why?
| | Antigenic Variation | 1 | 2011 | 9 | 0.100 |
Why?
| | Receptors, Interleukin-12 | 1 | 2011 | 6 | 0.100 |
Why?
| | Moloney murine leukemia virus | 1 | 2011 | 11 | 0.100 |
Why?
| | Thymus Gland | 1 | 2013 | 300 | 0.100 |
Why?
| | Recombinant Proteins | 2 | 2013 | 1308 | 0.100 |
Why?
| | Toll-Like Receptor 3 | 2 | 2014 | 31 | 0.100 |
Why?
| | RNA-Binding Proteins | 1 | 1995 | 371 | 0.100 |
Why?
| | Myocarditis | 1 | 2012 | 95 | 0.100 |
Why?
| | Viral Envelope Proteins | 1 | 2011 | 80 | 0.100 |
Why?
| | Transplantation, Homologous | 3 | 2017 | 415 | 0.100 |
Why?
| | Immunoglobulin E | 1 | 2012 | 365 | 0.100 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2022 | 112 | 0.100 |
Why?
| | Nasal Mucosa | 1 | 2011 | 97 | 0.090 |
Why?
| | Hyaluronan Receptors | 2 | 2009 | 93 | 0.090 |
Why?
| | Nucleic Acids | 1 | 2011 | 59 | 0.090 |
Why?
| | Time Factors | 1 | 2021 | 6412 | 0.090 |
Why?
| | Breast Neoplasms | 1 | 2022 | 1965 | 0.090 |
Why?
| | Body Weight | 1 | 2014 | 934 | 0.090 |
Why?
| | Macaca mulatta | 3 | 2019 | 153 | 0.090 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2015 | 814 | 0.090 |
Why?
| | Granzymes | 2 | 2022 | 40 | 0.090 |
Why?
| | Toll-Like Receptor 5 | 1 | 2009 | 15 | 0.090 |
Why?
| | Liver | 2 | 2016 | 1816 | 0.090 |
Why?
| | Polyethyleneimine | 1 | 2009 | 18 | 0.090 |
Why?
| | Organ Specificity | 2 | 2001 | 278 | 0.090 |
Why?
| | Toll-Like Receptor 8 | 2 | 2006 | 5 | 0.090 |
Why?
| | Injections, Intravenous | 2 | 2013 | 210 | 0.090 |
Why?
| | Amino Acid Sequence | 3 | 2016 | 2071 | 0.080 |
Why?
| | Autoimmune Diseases | 1 | 2012 | 398 | 0.080 |
Why?
| | Bronchial Hyperreactivity | 1 | 2009 | 95 | 0.080 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 465 | 0.080 |
Why?
| | Lectins, C-Type | 2 | 2020 | 63 | 0.080 |
Why?
| | Kupffer Cells | 1 | 2008 | 47 | 0.080 |
Why?
| | Protein Binding | 2 | 2022 | 1975 | 0.080 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1323 | 0.080 |
Why?
| | Mutation | 1 | 2019 | 3457 | 0.080 |
Why?
| | Tumor Microenvironment | 2 | 2022 | 454 | 0.080 |
Why?
| | Proto-Oncogene Proteins | 2 | 2002 | 618 | 0.080 |
Why?
| | Baculoviridae | 1 | 2008 | 46 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2012 | 688 | 0.080 |
Why?
| | Tumor Cells, Cultured | 2 | 2021 | 874 | 0.080 |
Why?
| | Saccharomyces cerevisiae | 1 | 2012 | 495 | 0.080 |
Why?
| | Insecta | 1 | 2008 | 68 | 0.080 |
Why?
| | Interferon Inducers | 2 | 2008 | 7 | 0.080 |
Why?
| | B7-1 Antigen | 3 | 2009 | 69 | 0.080 |
Why?
| | Major Histocompatibility Complex | 2 | 2008 | 220 | 0.080 |
Why?
| | Research Personnel | 1 | 2009 | 158 | 0.070 |
Why?
| | RNA, Small Interfering | 1 | 2009 | 564 | 0.070 |
Why?
| | Immunosuppressive Agents | 2 | 2009 | 681 | 0.070 |
Why?
| | Histocompatibility Antigen H-2D | 2 | 2008 | 21 | 0.070 |
Why?
| | Injections, Intradermal | 1 | 2006 | 11 | 0.070 |
Why?
| | Oleic Acids | 1 | 2006 | 13 | 0.070 |
Why?
| | Injections, Intraperitoneal | 2 | 2013 | 108 | 0.070 |
Why?
| | Mannitol | 1 | 2006 | 34 | 0.070 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2022 | 158 | 0.070 |
Why?
| | Inflammation Mediators | 1 | 2009 | 502 | 0.070 |
Why?
| | HIV Antigens | 1 | 2005 | 17 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2018 | 2220 | 0.070 |
Why?
| | Oligodeoxyribonucleotides | 4 | 2006 | 139 | 0.070 |
Why?
| | Neoplasms, Experimental | 1 | 2006 | 158 | 0.070 |
Why?
| | Nanoparticles | 1 | 2009 | 325 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2008 | 2851 | 0.070 |
Why?
| | Cell Adhesion | 1 | 2006 | 443 | 0.060 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 709 | 0.060 |
Why?
| | CD40 Ligand | 2 | 2018 | 46 | 0.060 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 1137 | 0.060 |
Why?
| | Genes, Reporter | 2 | 2002 | 270 | 0.060 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2004 | 49 | 0.060 |
Why?
| | Ovarian Neoplasms | 1 | 2009 | 420 | 0.060 |
Why?
| | Neoplasms | 2 | 2009 | 2179 | 0.060 |
Why?
| | Transfection | 3 | 2019 | 888 | 0.060 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2023 | 71 | 0.060 |
Why?
| | Genes, bcl-2 | 1 | 2002 | 20 | 0.060 |
Why?
| | Pregnancy | 1 | 2014 | 5691 | 0.050 |
Why?
| | Ubiquitin C | 1 | 2001 | 3 | 0.050 |
Why?
| | Asthma | 2 | 2012 | 2158 | 0.050 |
Why?
| | Interphase | 2 | 1999 | 30 | 0.050 |
Why?
| | Middle Aged | 3 | 2021 | 27617 | 0.050 |
Why?
| | Transcriptome | 2 | 2019 | 756 | 0.050 |
Why?
| | CTLA-4 Antigen | 2 | 2019 | 86 | 0.050 |
Why?
| | THP-1 Cells | 1 | 2021 | 20 | 0.050 |
Why?
| | Apoptosis | 1 | 2011 | 2484 | 0.050 |
Why?
| | Lymph Node Excision | 1 | 2022 | 158 | 0.050 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2022 | 359 | 0.050 |
Why?
| | Polymerization | 1 | 2022 | 129 | 0.050 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2001 | 133 | 0.050 |
Why?
| | Cytoskeletal Proteins | 1 | 2022 | 146 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2002 | 226 | 0.050 |
Why?
| | World Health Organization | 1 | 2022 | 107 | 0.050 |
Why?
| | Macromolecular Substances | 1 | 2001 | 201 | 0.050 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2023 | 197 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2001 | 770 | 0.050 |
Why?
| | Cell Line | 2 | 2005 | 2707 | 0.050 |
Why?
| | Tumor Burden | 1 | 2022 | 274 | 0.050 |
Why?
| | Intraepithelial Lymphocytes | 1 | 2020 | 12 | 0.050 |
Why?
| | Drosophila Proteins | 1 | 2002 | 171 | 0.050 |
Why?
| | Acrylic Resins | 1 | 2020 | 39 | 0.050 |
Why?
| | Receptors, Mitogen | 1 | 2020 | 8 | 0.050 |
Why?
| | Aged | 2 | 2016 | 19657 | 0.050 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2021 | 189 | 0.050 |
Why?
| | STAT3 Transcription Factor | 1 | 2022 | 189 | 0.050 |
Why?
| | Keratinocytes | 1 | 2021 | 227 | 0.050 |
Why?
| | Green Fluorescent Proteins | 1 | 2001 | 395 | 0.050 |
Why?
| | Mice, Inbred Strains | 1 | 2000 | 405 | 0.050 |
Why?
| | Gene Expression Profiling | 3 | 2002 | 1597 | 0.040 |
Why?
| | Lipopolysaccharides | 4 | 2006 | 870 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2022 | 1166 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 331 | 0.040 |
Why?
| | HIV-1 | 1 | 2005 | 776 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 2019 | 53 | 0.040 |
Why?
| | Clonal Anergy | 1 | 1999 | 54 | 0.040 |
Why?
| | Arthritis | 1 | 2020 | 112 | 0.040 |
Why?
| | Toxoplasmosis | 1 | 2019 | 31 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2001 | 653 | 0.040 |
Why?
| | Toxoplasma | 1 | 2019 | 34 | 0.040 |
Why?
| | Homozygote | 1 | 2019 | 190 | 0.040 |
Why?
| | Adult | 2 | 2021 | 31512 | 0.040 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1999 | 175 | 0.040 |
Why?
| | Survival Analysis | 1 | 2022 | 1267 | 0.040 |
Why?
| | Immunoconjugates | 1 | 1999 | 89 | 0.040 |
Why?
| | Siblings | 1 | 2019 | 235 | 0.040 |
Why?
| | Plasmids | 2 | 2011 | 355 | 0.040 |
Why?
| | Cations | 2 | 2009 | 79 | 0.040 |
Why?
| | Receptors, Immunologic | 1 | 2019 | 209 | 0.040 |
Why?
| | Genome | 1 | 2000 | 277 | 0.040 |
Why?
| | Acute Disease | 1 | 2020 | 940 | 0.040 |
Why?
| | Biomarkers | 2 | 2021 | 3588 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2001 | 1158 | 0.040 |
Why?
| | Cytomegalovirus Infections | 1 | 2019 | 187 | 0.040 |
Why?
| | Skin | 1 | 2021 | 657 | 0.040 |
Why?
| | Arenaviridae Infections | 1 | 2016 | 7 | 0.040 |
Why?
| | Cell Degranulation | 1 | 2016 | 38 | 0.040 |
Why?
| | Cell Separation | 2 | 2012 | 296 | 0.040 |
Why?
| | Lymphocytic choriomeningitis virus | 1 | 2016 | 20 | 0.040 |
Why?
| | Carboxymethylcellulose Sodium | 1 | 2015 | 3 | 0.030 |
Why?
| | Polylysine | 1 | 2015 | 19 | 0.030 |
Why?
| | CpG Islands | 2 | 2006 | 119 | 0.030 |
Why?
| | Cellular Senescence | 1 | 2016 | 151 | 0.030 |
Why?
| | Histocompatibility Testing | 1 | 2015 | 123 | 0.030 |
Why?
| | Disease Progression | 1 | 2022 | 2490 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2001 | 2871 | 0.030 |
Why?
| | Chronic Disease | 1 | 2020 | 1636 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2020 | 654 | 0.030 |
Why?
| | Hypodermoclysis | 1 | 2013 | 4 | 0.030 |
Why?
| | Down-Regulation | 2 | 2011 | 627 | 0.030 |
Why?
| | Models, Molecular | 1 | 2019 | 1435 | 0.030 |
Why?
| | Stem Cells | 1 | 1998 | 559 | 0.030 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2013 | 101 | 0.030 |
Why?
| | Species Specificity | 1 | 1995 | 565 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1012 | 0.030 |
Why?
| | Respiratory Mucosa | 1 | 2015 | 254 | 0.030 |
Why?
| | Immunological Synapses | 1 | 2012 | 18 | 0.030 |
Why?
| | Rats, Inbred Lew | 1 | 2012 | 87 | 0.030 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2015 | 613 | 0.030 |
Why?
| | Inflammation | 2 | 2020 | 2566 | 0.030 |
Why?
| | Particle Size | 1 | 2013 | 345 | 0.030 |
Why?
| | Interferon-alpha | 2 | 2005 | 191 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 333 | 0.030 |
Why?
| | Clodronic Acid | 1 | 2012 | 9 | 0.030 |
Why?
| | Interleukin-1 | 2 | 2012 | 980 | 0.030 |
Why?
| | Chemokine CXCL1 | 1 | 2012 | 69 | 0.030 |
Why?
| | Cattle | 1 | 1995 | 978 | 0.030 |
Why?
| | Diphtheria Toxin | 1 | 2012 | 63 | 0.030 |
Why?
| | Th17 Cells | 1 | 2012 | 57 | 0.030 |
Why?
| | Chemokine CCL2 | 1 | 2012 | 126 | 0.030 |
Why?
| | Melioidosis | 1 | 2011 | 4 | 0.030 |
Why?
| | Burkholderia pseudomallei | 1 | 2011 | 10 | 0.030 |
Why?
| | Bone Marrow | 1 | 2013 | 255 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 143 | 0.020 |
Why?
| | Aerosols | 1 | 2012 | 221 | 0.020 |
Why?
| | Administration, Intranasal | 1 | 2011 | 79 | 0.020 |
Why?
| | Models, Animal | 1 | 2013 | 363 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2012 | 656 | 0.020 |
Why?
| | Phylogeny | 1 | 1995 | 816 | 0.020 |
Why?
| | Lipoproteins | 1 | 2012 | 162 | 0.020 |
Why?
| | Cysteine | 1 | 2012 | 184 | 0.020 |
Why?
| | Weight Gain | 1 | 2013 | 493 | 0.020 |
Why?
| | Pulmonary Emphysema | 1 | 2013 | 327 | 0.020 |
Why?
| | Echocardiography | 1 | 2012 | 556 | 0.020 |
Why?
| | Methacholine Chloride | 1 | 2009 | 48 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2012 | 379 | 0.020 |
Why?
| | Prostaglandin D2 | 1 | 2008 | 23 | 0.020 |
Why?
| | Ischemia | 1 | 2012 | 374 | 0.020 |
Why?
| | Cell Death | 2 | 2001 | 339 | 0.020 |
Why?
| | CD4 Antigens | 1 | 2009 | 126 | 0.020 |
Why?
| | Heart | 1 | 2012 | 631 | 0.020 |
Why?
| | Metabolomics | 1 | 2013 | 550 | 0.020 |
Why?
| | Cell Transplantation | 1 | 2008 | 39 | 0.020 |
Why?
| | Dinoprostone | 1 | 2008 | 193 | 0.020 |
Why?
| | Cell Survival | 2 | 2002 | 1047 | 0.020 |
Why?
| | Risk Factors | 1 | 2021 | 9000 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2007 | 280 | 0.020 |
Why?
| | Zymosan | 1 | 2006 | 64 | 0.020 |
Why?
| | Nucleocapsid Proteins | 1 | 2005 | 24 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2008 | 544 | 0.020 |
Why?
| | Age Factors | 1 | 2013 | 2995 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2019 | 9342 | 0.020 |
Why?
| | Primates | 1 | 2005 | 114 | 0.020 |
Why?
| | Rats | 1 | 2012 | 5392 | 0.010 |
Why?
| | Ligands | 1 | 2005 | 567 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2006 | 394 | 0.010 |
Why?
| | Mycobacterium tuberculosis | 1 | 2006 | 266 | 0.010 |
Why?
| | Nitric Oxide | 1 | 2008 | 892 | 0.010 |
Why?
| | bcl-X Protein | 1 | 2002 | 41 | 0.010 |
Why?
| | Superantigens | 1 | 2002 | 68 | 0.010 |
Why?
| | Interleukin-3 | 1 | 2002 | 25 | 0.010 |
Why?
| | Receptors, CCR7 | 1 | 2002 | 24 | 0.010 |
Why?
| | Models, Immunological | 1 | 2002 | 94 | 0.010 |
Why?
| | Receptors, Chemokine | 1 | 2002 | 45 | 0.010 |
Why?
| | Chemokines, CXC | 1 | 2002 | 64 | 0.010 |
Why?
| | RNA, Messenger | 2 | 2000 | 2657 | 0.010 |
Why?
| | Genetic Variation | 1 | 2007 | 926 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 6561 | 0.010 |
Why?
| | Aging | 1 | 2011 | 1670 | 0.010 |
Why?
| | Cell Division | 1 | 2002 | 776 | 0.010 |
Why?
| | Phorbol Esters | 1 | 2000 | 16 | 0.010 |
Why?
| | Expressed Sequence Tags | 1 | 2000 | 38 | 0.010 |
Why?
| | Jurkat Cells | 1 | 2000 | 134 | 0.010 |
Why?
| | Abatacept | 1 | 1999 | 42 | 0.010 |
Why?
| | Nucleic Acid Hybridization | 1 | 1999 | 193 | 0.010 |
Why?
| | Antigens, Differentiation | 1 | 1999 | 79 | 0.010 |
Why?
| | Immunization, Secondary | 1 | 1999 | 85 | 0.010 |
Why?
| | Hybridomas | 1 | 1999 | 233 | 0.010 |
Why?
| | Antioxidants | 1 | 2002 | 564 | 0.010 |
Why?
| | NF-kappa B | 1 | 2002 | 670 | 0.010 |
Why?
| | Hot Temperature | 1 | 2000 | 334 | 0.010 |
Why?
| | Databases, Factual | 1 | 2000 | 1231 | 0.010 |
Why?
|
|
Kedl's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|